BIXT: Bioxytran, Inc. Stock

by  •  • Comments Off on BIXT: Bioxytran, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 19.25
Enterprise Value ($M) 19.54
Book Value ($M) -0.99
Book Value / Share -0.01
Price / Book -19.43
NCAV ($M) -1.11
NCAV / Share -0.01
Price / NCAV -17.40

Profitability (mra)
Return on Invested Capital (ROIC) -350.75
Return on Assets (ROA) -18.39
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.01
Current Ratio 0.01

Balance Sheet (mrq) ($M)
Current Assets 0.01
Assets 0.13
Liabilities 1.12
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -3.83
Net Income -4.28
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -0.78
Cash from Investing -0.04
Cash from Financing 0.55

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-22 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION R
2024-04-19 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O
2023-11-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-07-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-30 41,978 47,558 88.27
2024-04-29 49,700 91,490 54.32

(click for more detail)

Similar Companies
BIEI – Premier Biomedical, Inc. BIMT – Bitmis Corp.
BIOE – Bio Essence Corporation BLFE – BioLife Sciences Inc.
BLMS – Bloomios, Inc.


Financial data and stock pages provided by
Fintel.io